Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy

Mathur, Vijay; Parihar, Jitendra Kumar Singh; Maggon, Rakesh; Mishra, SK

doi:10.1016/s0377-1237(09)80092-0

Cited by 7 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Instead, Mathur et al used a different protocol on 25 patients, using spot of 1.2 mm, with power of 120-200 mW and 2-3 s of exposure. After 2 months of treatment, out of 25 patients, 52% had SRF resolution and BCVA improvement ≥2 lines, 42% showed only SRF resolution and 8% had persistent SRF [83].…”

Section: Transpupillary Thermal Therapy (Ttt)mentioning

confidence: 98%

Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options

Sartini

Figus

Nardi

et al. 2019

Eye

View full text Add to dashboard Cite

Central serous chorioretinopathy is one of the most frequent causes of vision reduction among middle-aged men. This disease usually has a self-limiting course, but sometimes it lasts more than 4-6 months or a second episode follows a complete resolution of the first one. Nevertheless, to date no consensus exists about the duration threshold and therapy protocols for these non-resolving central serous chorioretinopathy. Treatment as half-dose and half-fluence photodynamic therapy, subthreshold micropulse laser treatment, mineralocorticoid receptor antagonists, intravitreal anti-angiogenic drugs, transpupillary thermal therapy, anti-androgenic drugs, methotrexate, Rifampicin and melatonin are described in this review. Complications are very uncommon but end-point results like central macular thickness reduction and best-corrected visual acuity improvement are difficult to compare among different therapeutic modalities due to different duration of follow-up and lack of homogeneity in patient recruitment. The aim of this review is focusing on treatment modalities for these chronic forms with comprehensive recent management updates according to latest clinical trial results.

show abstract

Section: Transpupillary Thermal Therapy (Ttt)mentioning

confidence: 98%

Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options

Sartini

Figus

Nardi

et al. 2019

Eye

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…There are many well-developed medical treatments for CSCR; however, they are associated with various serious side effects that are dangerous and even fatal for patients. In addition, a laser approach, such as argon laser photocoagulation (ALP), photodynamic therapy (PDT), or trans-pupillary thermotherapy (TTT), has been used for treating CSCR [27]. Nowadays, CSCR is well-studied and is associated with a type A behavior pattern which, in turn, is associated with physiological changes, including increased blood pressure and elevated serum cortisol and epinephrine levels.…”

Section: Discussionmentioning

confidence: 99%

Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets

Chen

Shieh

et al. 2020

Pharmaceuticals

View full text Add to dashboard Cite

Purpose: To evaluate the pharmacological effects of propranolol treatment of patients with central serous chorioretinopathy (CSCR) over 4 months. Results: Among the 89 male and 31 female patients, the mean BCVA decreased to 0.42 ± 0.08 logMAR during CSCR attacks. Oral propranolol showed good effectiveness in reducing CSCR signs after at least 4 months of treatment. The final BCVA of the patients in groups 1 and 2 was 0.09 ± 0.01 and 0.19 ± 0.03 logMAR, respectively (p < 0.05). Moreover, the mean complete remission time in groups 1 and 2 was 1.9 and 3.5 months, respectively (p < 0.05), while the “success” rate in groups 1 and 2 was 95.0% (57/60) and 78.3% (47/60), respectively (p < 0.05). The recurrence rate in groups 1 and 2 was 5.3% (3/57) and 25.5% (12/47) after a further 5 months of follow-up, respectively (p < 0.05). Materials and Methods: One hundred and twenty patients were enrolled and randomly divided into two groups that both underwent a visual acuity test and optical coherence tomography (OCT) scanning, between April and December 2017. The 60 patients in group 1 were requested to take propranolol for 4 months, while the other 60 subjects (group 2) received placebo therapy during the same period. The best-corrected visual acuity (BCVA) of every volunteer and an OCT image of each patient were checked and recorded at the beginning of the study and each week thereafter. If the signs of CSCR disappeared completely from the OCT scans, the case was considered a “success” and treatment stopped at once. However, the “success” subjects were further evaluated in follow-ups throughout the next 5 months to determine the rate of recurrence in groups 1 and 2. The time of total complete remission of CSCR from the OCT scans was also measured in groups 1 and 2. Conclusion: CSCR patients revealed an excellent prognosis and success rate of 95.0% after taking propranolol. The treatment was able to enhance subretinal fluid (SRF) absorption, shorten the time to total complete remission, and significantly decrease CSCR recurrence. As such, we suggest that taking propranolol may be an alternative and viable choice for CSCR patients, given that the new method was shown to be safe, cheap, effective, well tolerated and convenient.

show abstract

“…Локальная гипертермия приводит к каскаду реакций с выработкой белков теплового шока, способных восстанавливать работу ПЭС. Эффективность ТТТ составляет 40-96 % по данным разных исследователей в зависимости от протоколов проводимой термотерапии, разрабатываемых и по сей день [5,[17][18][19][20][21][22].…”

Section: лечение пациентов с цсхunclassified

Current Approach to Treatment for Central Serous Chorioretinopathy. Review

Дракон¹,

Патеюк²,

Sheludchenko³

et al. 2021

Oftalʹmologiâ

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC) is a disease of complex origin and unknown etiology. Traditionally, two clinical forms of CSC are verified in accordance with the activity and duration of the pathological process: classic acute form and chronic CSC. Nowadays, there is no unified concept accepted for the management of patients with this disease, particular difficulties exist in cases of chronic CSC. This literature review highlights current trends and approaches to the treatment of CSC patients — from focal laser photocoagulation to physical methods oh therapy. The therapeutic approach as a whole depends on the form of the CHS. In most cases of the acute form of CSF, spontaneous regression, spontaneous adhesion of RPE detachment and retinal neuroepithelium are noted within several months from the onset of the disease. Therapy for the chronic form of this disease is still a difficult task and a controversial issue. Direct laser coagulation of the retina at the oozing point is recognized as the most effective method of therapy for acute typical form of CSF. In the chronic form of CSC, photodynamic therapy, transpupillary thermotherapy and subthreshold micropulse laser exposure are used. The goal of drug therapy for CSF is to activate the processes of resorption of serous fluid from the subretinal or subpigmented space, reduce the activity of pathological processes in the choroid, and improve trophism and metabolism. The currently used methods of treating chronic CSH have a number of disadvantages and variable efficacy. The existence of treatment-resistant cases is the subject of further research and clinical research. The development of new physical and physiopharmacological methods of treatment for CSF is perspective.

show abstract

Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy

Cited by 7 publications

References 10 publications

Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options

Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options

Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets

Current Approach to Treatment for Central Serous Chorioretinopathy. Review

Contact Info

Product

Resources

About